Cancer screening cadence

A handful of cancer screening tests genuinely save lives in the people they were designed for. Several others mostly find cancers that would never have caused harm — so the useful question is not how much screening you do, but which tests, and when.

For two generations the framing was simple: more screening, earlier, for everyone, saves lives. The 2022–2026 evidence has not overturned that picture so much as compressed it. A few modalities — biennial mammography from 40, colonoscopy or stool testing from 45, primary human papillomavirus (HPV) testing from 30, low-dose CT in heavy ever-smokers, one-time hepatitis C and abdominal aortic aneurysm screens in defined groups — sit on robust mortality data. The rest carry net benefit only in narrow risk strata, and a handful of routine tests now have a documented overdiagnosis problem that rivals or exceeds their mortality benefit. The largest randomized cancer-screening meta-analysis of the modern era found that across six common modalities, mean life-extension is measured in days, not years. That is the calibration this article is built around.

The first reframe: disease-specific vs all-cause mortality

A screening test can prevent death from cancer X without measurably extending the average life of the screened population. The 2023 JAMA Internal Medicine meta-analysis of 18 randomized trials in 2.1 million participants quantified exactly how compressed that gain is when averaged across everyone screened, including those who never had the disease and those who avoid cancer death only to die of something else.^[1]

Modality	Mean lifetime gained per person screened
Sigmoidoscopy	110 days
Low-dose CT (lung)	107 days
Prostate-specific antigen (PSA)	37 days
Colonoscopy	37 days
Mammography (biennial 50–69)	0 days
Fecal occult blood test	0 days

These are means, and a mean of zero is compatible with substantial individual benefit — the woman whose Stage I tumor was caught at mammography gains years; the millions of women who never develop breast cancer gain none. But the population frame is the one the policy decision sits on, and it argues for a small number of high-value tests done well, not a long list done because they exist.

A reasonable counter-fear — that screening kills patients indirectly, through false-positive cascades, radiation, or unnecessary procedures — was tested in a 2025 JAMA Network Open meta-analysis of 17 randomized trials in 1.3 million participants. Deaths from non-cancer causes rose by 0.2% in the screened arms, a difference statistically indistinguishable from zero.^[2] Screening doesn't passively harm. It just earns less than its marketing implies.

Colorectal — start at 45, complete what you start (Strong)

The US Preventive Services Task Force (USPSTF) lowered the colorectal cancer (CRC) screening initiation age from 50 to 45 in May 2021, prompted by a roughly 2%/year rise in early-onset CRC among under-50s. Grade B from 45 to 49; Grade A from 50 to 75; individualized 76–85.^[3] Clinicians adopted it fast: in one large US health system, screening orders for 45–49-year-olds had nearly caught up with those for 50-year-olds within five months of the change.^[4]

The interesting evidence is NordICC, the first large randomized controlled trial (RCT) of screening colonoscopy itself, randomizing 84,585 healthy 55–64-year-olds in Poland, Norway, Sweden, and the Netherlands.^[5] After 10 years, the intention-to-screen analysis showed CRC incidence of 0.98% in the invitation arm vs 1.20% in usual care — an 18% relative reduction. CRC-specific mortality was 0.28% vs 0.31%, not statistically significant.

The signal-to-noise problem was adherence: only 42% of those invited actually showed up for the colonoscopy. A per-protocol model assuming 100% adherence reconstructs a 31% incidence reduction and 50% mortality reduction. The honest reading is that colonoscopy works when it happens, and the headline harm of the trial is the dropout rate. A 2024 reanalysis of all-cause mortality found no signal at all on absolute lifespan even under the perfect-adherence model — the disease-specific gain gets absorbed by competing mortality in the 55–75 window.

What this means in practice. Start at 45. Use the modality you will actually complete. Annual fecal immunochemical test (FIT) at scale delivers comparable mortality reduction to 10-yearly colonoscopy in modeling — and modeling assumes you do it. Adherence is the variable that actually moves the outcome.

Breast — biennial from 40, with one open question (Strong)

The USPSTF moved the initiation age for screening mammography from 50 to 40 in April 2024, Grade B for biennial screening through age 74.^[6] The driver was a 2%/year rise in invasive breast cancer incidence in the 40–49 cohort between 2015 and 2019, plus modeling that initiating at 40 averts an additional ~1.3 breast cancer deaths per 1,000 women screened over a lifetime — and roughly 10.7 deaths per 1,000 in non-Hispanic Black women, whose mortality rate is 40% higher.

Two clinical scenarios still carry an "I" statement — insufficient evidence rather than affirmative recommendation:

Screening beyond age 75. No trial data; competing mortality starts to dominate.
Supplemental ultrasound or MRI for dense breasts (~40% of screened women). MRI undeniably finds more tumors. No RCT has yet shown that detection translates into fewer breast cancer deaths.

The DCIS overdiagnosis problem

Ductal carcinoma in situ (DCIS) — "Stage 0" — accounts for about 18% of newly diagnosed breast cancers in the US, almost all of it detected only because of screening.^[7] A micro-simulation model of biennial screening from age 50 estimates that roughly 1 in 5 detected DCIS cases is overdiagnosis — 20%, with a plausible range of 13–30%, and little variation by tumor grade.^[8] The historical response to any DCIS has nonetheless been immediate surgery.

What happens when that surgery is not done is now measurable. An observational cohort of 1,780 US women whose DCIS was not operated on within six months found invasive cancer in the same breast in 8–14% of them at eight years — 8.5% in the low-risk group, 13.9% in the high-risk group — sharply below the 20–50% lifetime progression assumed by the older models that justified routine lumpectomy plus radiation plus endocrine therapy. Eight-year survival free of breast-cancer death was 96.4% overall and 98.1% in the low-risk group.^[9] The COMET active-surveillance trial is now testing directly whether the standard aggressive treatment of low-risk DCIS is itself the harm.

The site's overall framing applies: screening doesn't cause cancer, but it does manufacture cancer diagnoses, and that distinction matters for what you do with a "Stage 0" result.

Cervical — primary HPV, every five years (Strong)

Primary testing for high-risk strains of human papillomavirus (HPV) detects 40% more high-grade precancerous lesions — grade 3 cervical intraepithelial neoplasia or worse, the stage just short of invasion — and 30% more cervical cancers per screening round than liquid-based cytology. In the round after a negative HPV test, the odds of such a lesion are about seven-fold lower than after negative cytology.^[10] On that basis the UK, the Netherlands, and the European Commission's screening guidance extend the interval to 5 years for HPV-negative women (longer in some models for women 40+).^[11]

The behavioral catch is that women habituated to a 3-year cytology cadence often experience the longer interval as undertreatment. The biology argues the other way — persistent HPV infection takes years to progress through cellular dysplasia to invasive cancer, and a negative HPV test has a very high forward negative predictive value. Patient education is the actual implementation problem; the science isn't.

Prostate — risk-stratified PSA, not population PSA (Moderate)

The two-decade transatlantic argument between ERSPC (mortality benefit) and PLCO (no benefit) has largely been resolved by recognizing that PLCO's control arm was massively contaminated by opportunistic prostate-specific antigen (PSA) testing outside the trial.^[12] Adjusting for mean lead time — the average amount of time by which screening brings a diagnosis forward — makes the two trials roughly compatible, with PSA screening conferring a 7–9% reduction in prostate cancer death per year of lead time.

At 23 years of follow-up across 162,236 men, ERSPC shows 13% lower prostate cancer mortality in the screened group (rate ratio 0.87, 95% CI 0.80–0.95).^[13] The bracketed range here and below is a confidence interval — the span in which the true effect most plausibly lies; when such a range crosses 1.0, the result is compatible with no effect at all. In absolute terms the benefit is much smaller than "13%" sounds: about 2 fewer prostate cancer deaths per 1,000 men invited over 23 years. To prevent one prostate cancer death, 456 men must be invited to screen and 12 must be diagnosed and treated.

The implication is not "PSA doesn't work." It is that untargeted PSA testing on every adult man generates a large overdiagnosis and overtreatment cost — incontinence, erectile dysfunction, the cardiovascular morbidity of androgen deprivation — for a small absolute mortality gain. Modern urological guidelines and several European national programs are converging on a stratified pathway: baseline PSA, longer intervals for low values, multiparametric MRI before any biopsy, and active surveillance for Gleason 6 disease. Discuss the test; don't reflexively order it.

Lung — low-dose CT in actual heavy smokers (Strong)

The USPSTF 2021 update broadened low-dose CT (LDCT) eligibility to adults 50–80 with a history of at least 20 pack-years — one pack a day for 20 years, or the equivalent — who currently smoke or quit within 15 years.^[14] Stop screening once a person has been off cigarettes for 15 years or develops a comorbidity that would rule out curative surgery.

LDCT works because it catches small, operable nodules years before symptoms. False positives are common (benign granulomas and hamartomas light up the same way), and serial surveillance scans, bronchoscopy, and needle biopsy of benign tissue are part of the cost — which is why the eligibility criteria are tight. Screening is highly cost-effective in the target population and not justified outside it.

Skin — not routinely (Insufficient evidence)

The USPSTF gives an "I" statement to routine clinician-performed visual skin checks in asymptomatic adults.^[15] A pooled review of 20 studies in over 6 million patients found no population-level melanoma mortality benefit. Routine screening finds a great deal of Stage 0 / Stage I melanoma — much of which appears to be indolent — without proportionally reducing late-stage, lethal nodular melanoma, which often progresses rapidly between screening intervals (length-time bias).

This isn't an argument against dermatologic care for visible suspicious lesions or for patients with high-risk family history, very fair skin that burns rather than tans, or many atypical moles. It is an argument against the routine annual "skin check" as a population-wide longevity lever.

Hepatitis C and aortic aneurysm — one-time, defined-population screens (Strong)

Two screening tests deliver outsized benefit relative to their effort because they are one-time, well-targeted, and curative or definitively actionable downstream.

Hepatitis C, one-time, all adults 18–79. With direct-acting antivirals achieving cure rates well above 95%, the case for universal one-time hepatitis C virus (HCV) antibody screening — with an automatic follow-up test for viral genetic material if the antibody is positive — is now overwhelming; the USPSTF dropped the prior birth-cohort and risk-based framing in 2020.^[16] Hepatitis B remains risk-stratified.
Abdominal aortic aneurysm (AAA) — one-time ultrasound, men 65–75 who have ever smoked. The USPSTF criterion is narrow because that is where the survival benefit concentrates. The 2024 European Society for Vascular Surgery guidelines emphasize the same point: defer CT angiography and surgical planning until the operative threshold (about 55 mm in men, 50 mm in women) is met, and route patients to volume-adequate centers (at least 15 open and 15 endovascular repairs annually).^[17]

The overdiagnosis problem — visible most in thyroid (Caution)

Overdiagnosis isn't a screening failure mode; it's a screening byproduct. The clearest illustration is thyroid cancer: global incidence has surged for three decades while mortality has stayed flat. Modeling using a validated papillary thyroid carcinoma microsimulation framework estimates that 72% to 94% of all US papillary thyroid cancer diagnoses between 1991 and 2019 were overdiagnoses — clinically silent lesions that would never have surfaced symptomatically.^[18] Several hundred thousand people received total thyroidectomy, radioactive iodine, and lifelong thyroid hormone replacement for a "cancer" that didn't behave like one. See Thyroid management for the active-surveillance reframe that the 2025 American Thyroid Association guidelines have now formally adopted.

Site	Estimated overdiagnosis	What it produces
Papillary thyroid	72–94% of detected cases (US 1991–2019)	Thyroidectomy; lifelong thyroid hormone replacement; risk of parathyroid injury and lasting calcium problems
DCIS (breast)	~20% of screen-detected cases	Lumpectomy ± radiation ± endocrine therapy
Localized prostate (PSA-detected)	Substantial; "12 diagnoses to prevent 1 death"	Prostatectomy / radiation; incontinence; erectile dysfunction
Stage 0/I melanoma	Indolent share of rising incidence	Excisional surgery; psychological burden

The defensive principle is to screen only where evidence supports the cadence, take overdiagnosis seriously when deciding what to do with an early-stage result, and prefer active surveillance over reflex resection when the evidence supports it (DCIS, low-grade prostate, sub-centimeter thyroid nodules).

Multi-cancer early detection (MCED) — promising, not ready (Weak / preliminary)

The biggest unsolved problem in cancer screening is that the large majority of cancer deaths — on most estimates around 85–90% — come from cancers with no guideline-recommended screening test at all. Multi-cancer early detection (MCED) assays — blood tests that read chemical tags on tumor DNA shed into the bloodstream, of which Galleri is the most prominent — promise to find dozens of cancers from a single draw. (The systematic review this section draws on for test performance has now been published in full as a UK National Institute for Health and Care Research assessment monograph. It synthesises the studies narratively rather than pooling them statistically, so read the figures below as the range across trials, not as a single meta-analytic estimate.)^[19]

The first large interventional readout is the NHS-Galleri trial in over 142,000 asymptomatic 50–77-year-olds. As of writing it exists only as a company press release — there is no peer-reviewed publication, so every figure below is the manufacturer's own account of its own trial.^[20] The headlines are mixed:

Primary endpoint missed: no statistically significant reduction in combined Stage III/IV cancer incidence in the intervention arm.
Stage shift in the right direction: substantial absolute increase in Stage I/II detection across 12 typically late-presenting cancers, and a ~4× higher overall detection rate when added to standard screening.
Reduction in emergency-presentation diagnoses — meaningful for both prognosis and acute healthcare cost.
Adherence reassurance: women with negative Galleri results maintained >80% adherence to standard mammography, against the worry that a negative blood test would seed false confidence.

The cautious read is that MCED tests find earlier-stage cancers without yet showing they prevent late-stage cancers — a pattern entirely compatible with detecting indolent disease faster rather than aggressive disease earlier. That distinction is the whole argument, and national screening bodies have made it explicit: a stage shift is a surrogate outcome, and a surrogate is only trustworthy once it has been shown to track the outcome that matters.^[21] On that reasoning the UK National Screening Committee's 2026 position is that MCED tests require randomized evidence of reduced cancer mortality — or of reduced late-stage disease — before they can be recommended for population screening; professional oncology societies and the USPSTF take the same line.^[22] Insufficient evidence to recommend MCED for routine population screening outside clinical trials remains the consensus. That position will likely move once a randomized trial shows a hard mortality endpoint. It hasn't yet.

Practical guidance

Run the evidence-backed cadence and complete it. Colorectal from 45 (colonoscopy or annual FIT — the one you'll actually do). Mammography biennially from 40 to 74. Primary HPV every 5 years 30–65. Low-dose CT annually if you meet the 50–80 / 20+ pack-year / ≤15 years quit criteria. One-time HCV antibody if you've never been tested. One-time AAA ultrasound for men 65–75 with any smoking history.
Have the PSA conversation; don't reflex-order it. Shared decision around age 50 (45 with family history or African ancestry); use baseline-stratified intervals and demand multiparametric MRI before any biopsy if you do screen.
Take overdiagnosis seriously when you get a result. A Stage 0 finding (DCIS, ≤1 cm thyroid nodule, Gleason 6 prostate) doesn't automatically mean immediate surgery — active surveillance is now standard-of-care in defined low-risk subsets.
Don't add tests that lack evidence. Routine whole-body skin checks, opportunistic neck ultrasound, full-body MRI marketed to healthy adults, and MCED panels outside trials all currently sit closer to harm than benefit on the population evidence.
Recognize that screening reduces cancer mortality, not necessarily all-cause mortality. The mean life-extension in the trial data is small. The behavioral levers — not smoking, blood pressure, lipids, sleep, exercise, weight — still dominate the longevity arithmetic.

What's overrated

Whole-body MRI and CT for healthy adults. Marketed aggressively; no RCT evidence of mortality benefit; substantial false-positive cascade.
Routine annual dermatologic skin checks in average-risk asymptomatic adults — the population data show stage shift without lethal-melanoma mortality reduction.
Opportunistic neck ultrasound for nonpalpable thyroid nodules — the modality that produced an iatrogenic cancer epidemic.
MCED tests as currently sold — biologically impressive, not yet shown to reduce the cancers people actually die of.